Although eicosanoid production contributes to physiological and pathophysiological consequences of cardiopulmonary bypass (CPB), the mechanisms accounting for the enhanced eicosanoid production have not been defined. Plasma phospholipase A2 (PLA2) activity, 6-keto-prostaglandin Fla (6-keto-PGF1,), and thromboxane B2 (TXB2) levels were measured at various times during cardiac surgery. Plasma PLA2 activity increased after systemic heparinization, before CPB. This was highly correlated with concurrent increases in plasma 6-keto-PGF,.. TXB2 concentrations did not increase with heparin administration but did increase significantly after initiation of CPB. High plasma PLA2 activity, 6-keto-PGF,., and TXB2 concentrations were measured throughout the CPB period. Protamine, administered to neutralize the heparin, caused an acute reduction of both plasma PLA2 activity and plasma 6-keto-PGF1,r, but no change in plasma TXB2 concentrations. Thus the ratio of TXB2 to 6-keto-PGFia increased significantly after protamine administration. Enhanced plasma PLA2 activity was also measured in patients with lower doses of heparin used clinically for nonsurgical applications. Human plasma PLA2 was identified as group II PLA2 by its sensitivity to deoxycholate and dithiothreitol, its substrate specificity, and its elution characteristics on heparin affinity chromatography.
throughout the CPB period. Protamine, administered to neutralize the heparin, caused an acute reduction of both plasma PLA2 activity and plasma 6-keto-PGF1,r, but no change in plasma TXB2 concentrations. Thus the ratio of TXB2 to 6-keto-PGFia increased significantly after protamine administration. Enhanced plasma PLA2 activity was also measured in patients with lower doses of heparin used clinically for nonsurgical applications. Human plasma PLA2 was identified as group II PLA2 by its sensitivity to deoxycholate and dithiothreitol, its substrate specificity, and its elution characteristics on heparin affinity chromatography.
Heparin addition to PMNs in vitro resulted in dose-dependent increases in cellular PLA2 activity and release of PLA2. The PLA2 released from the PMN had characteristics similar to those of post-heparin plasma PLA2.
In conclusion, plasma PLA2 activity and 6-keto-PGF1, concentrations are markedly enhanced with systemic heparinization. Part of the anticoagulant and vasodilating effects of heparin may be due to increased plasma prostacyclin (PGI2) levels. In addition the pulmonary vasoconstriction sometimes associated with protamine infusion during car-Introduction Cardiopulmonary bypass (CPB)' has been associated with increased plasma concentrations of prostacycin (PGI2) and thromboxane A2 (TXA2), measured as the stable metabolites, 6-ketoprostaglandin Fla (6-keto-PGFia) and thromboxane B2 (TXB2) (1) (2) (3) (4) (5) . Another eicosanoid, leukotriene B4 , also has been found in pulmonary edema fluid after CPB (6) . PGI2, the major arachidonate metabolite of endothelial cells, is a potent vasodilator and inhibits platelet aggregation. TXA2, the predominant cyclooxygenase product of arachidonic acid in platelets, induces vasoconstriction and platelet aggregation and has been implicated in the etiology of pulmonary hypertension sometimes seen with cardiac surgery after protamine infusion for neutralization of heparin (7-1 1). It has been suggested that increased synthesis or imbalance in the relative synthesis of these potent vasoactive eicosanoids may contribute to organ dysfunction in various pathological states (12) and result in depressed renal, pulmonary, and cardiac function as well as thrombocytopenia, significant problems after cardiac surgery. It is not known, however, why eicosanoid production is enhanced with CPB.
Phospholipases A2 (PLA2) comprise a family of enzymes that hydrolyze membrane phospholipids at the sn-2 position to release fatty acids and lysophospholipids (13) . Different forms of PLA2 are involved in digestion, inflammation, and intracellular and intercellular signaling. Some forms are secreted, while others act intracellularly. When PLA2 acts upon lipids containing arachidonic acid in the sn-2 position the resulting free arachidonic acid can serve as a substrate for cyclooxygenases and lipoxygenases. Platelet damage or excess secretion of humoral factors such as catecholamines or angiotensin II during cardiac surgery (14) (15) (16) has been implicated in the elevation of cellular PLA2 activity. Complement activation during CPB (17) causes chemotaxis and leukosequestration, together with the production of oxygen free-radicals by neutrophils, which is thought to affect PLA2 activity (18) .
We report that high-dose heparin administration during surgery, before CPB, increases plasma PLA2 activity. Furthermore, this increase in plasma PLA2 activity is directly correlated with 1 . Abbreviations used in this paper: 2-[l1-'4C]AA-GPC, I-stearoyl-2- were selected for study with institutional approval and informed consent.
Each patient was anesthetized with fentanyl (100 ag/kg) and muscle relaxants. All received identical preoperative and perioperative medications, except one patient who received low dose (500 U/h) heparin infusion preoperatively for anticoagulation therapy. For CPB, a bubble oxygenator and nonpulsatile flow pump were used and systemic hypothermia (24°C) was maintained. 10 serial measurements were performed as follows: period 1, Control: after placement of monitoring catheters before induction of anesthesia; period 2, Anesthesia: 10 min after induction of anesthesia before incision; period 3, Before heparin: after incision, before heparin administration; period 4: 5 min after heparin administration (300 U/kg intravenously); periods 5-7: at 15, 30 , and 60 min on CPB, respectively; period 8: Before protamine administration; period 9: 5 min after protamine administration (3 mg/kg); and period 10: at the end of the operation. At each point, hemodynamic determinations and arterial blood gas measurements were performed. Arterial blood samples were transferred immediately into glass tubes containing EDTA for measurement of PLA2 activity. Indomethacin was added to samples to be analyzed for plasma 6-keto-PGFI,a and TXB2. Samples were centrifuged at 1,700 g for 20 min at 4°C, and plasma was stored at -70°C until assayed. Plasma heparin levels were determined by the heparin anti-IOA functional assay (chromostrate assay; Organon Teknika).
Experiments were performed to determine if lower doses of heparin also resulted in elevation in plasma PLA2 activity. In three patients blood was taken before and 5 min after a bolus of 5,000-6,000 U of heparin and in two patients blood was taken while they were receiving 1,400-1,500 U/h of heparin by continuous infusion.
Plasma prostaglandin assays
Plasma stable metabolites of TXA2 and PGI2, TXB2 and 6-keto-PGF1,, respectively, were measured by double antibody radioimmunoassay (19) .
Isolation ofpolymorphonuclear leukocytes
Polymorphonuclear leukocytes (PMNs) were prepared from fresh human blood using a method described previously (20) was determined using a different method (22) . Substrate 2-[1-'4C]AA-GPE was dried down with an N2 gas stream and resuspended in ethanol by vigorous vortexing. The PLA2 assay buffer (100 k1) contained 75 mM Tris-HCl, 5 mM CaCl2, and 0.5 nmol of the phospholipid (-65,000 cpm) at pH 8.5 . The reaction was carried out at 37°C for 30 min and was stopped by adding 0.56 ml of Dole's reagent: 48.75% isopropyl alcohol, 50% n-heptane, 1 .25% 1 N H2SO4 in water (23). Free fatty acid was extracted in the following manner: 0.11 ml of water was added and the sample was vortexed and centrifuged for 3 min. 0.15 ml of the upper phase was transferred to a new tube to which 25 mg silica gel and 0.8 ml of n-heptane were added. The samples were vortexed and centrifuged again for 3 min each. 0.8 ml of supernatant was then counted in a liquid scintillation counter.
PLA2 activity intrinsic to PMNs and released from PMNs and endothelial cells
After incubation of PMNs for 20 min with various doses of heparin (0, 1, 10, and 100 U/ml) at 37°C, samples were centrifuged at 3,000 g for 30 min, and PLA2 activity was measured in the supernatant to determine the release of enzymatic activity by PMNs into the medium. PMNs were washed twice with the same buffer not containing heparin, homogenized with 25 strokes of a tight Dounce homogenizer, and then centrifuged at 100,000 g at 4°C for 60 min. PLA2 activity in the 100,000 g supernatant was measured as described above and taken to be the intrinsic soluble PMN PLA2 activity. Human umbilical endothelial cells were grown in M199 medium with 20% fetal bovine serum. Endothelial cell medium PLA2 activity was measured under control conditions and after exposure of the cells to heparin (15 U/ml) for periods up to 24 h. Heparin-5PW HPLC column chromatography. Human plasma samples were diluted 1:1 with buffer A (50 mM Tris-HCl, 1 mM EDTA, pH 7.4) and loaded onto a heparin-5PW HPLC column (0.75 x 7.5 cm) preequilibrated with buffer A. Activity was eluted with buffer A (nonbinding fraction) at 1 ml/min for 20 min. Additional activity was then eluted with a linearly increasing gradient from 0 to 2 M of NaCl concentration in buffer A.
Chromatographic characterization of PLA2 activity
Ca2" dependency ofplasma PLA2 activity Aliquots of plasma samples were diluted 1:8 with buffers containing 140 mM NaCl, 25 mM Hepes, and varying amounts of CaCl2 with or without 1 mM EGTA, at pH 8.5. Enzymatic activity was determined after an aliquot of the mixture was taken to measure the free Ca2+ concentration. Enzymatic activity and free Ca2+ concentration were measured at 37°C. Ca2+ concentrations below 1 pM were determined using the dual wavelength fluorescence characteristics of Fura-2 free acid with a dual wavelength spectrofluorometer (Deltascan; Photon Technology Inc., Princeton, NJ). For concentrations > 1 ,uM, the free Ca2+ concentration of the assay buffer was determined with a Ca2" selective electrode, which we constructed and calibrated as described previously (24) . pH dependency ofplasma PLA2 activity Plasma samples were diluted with buffers of different pH (pH 5.0-11.0). Tris-HCI buffers were used to make up solutions at pH c 7.5, and glycine-NaOH buffers were used for pH 8.0 and above. Actual pH and PLA2 activity of each sample were determined in the presence of 3 mM Ca2+ (1 mM greater than the sum of the EGTA and EDTA concentrations in the assay buffer).
Effect of patients' plasma on porcine pancreatic PLA2 
Results
Plasma PLA2 activity during CPB surgery. As shown in Fig.   1 , plasma PLA2 activity before anesthesia was 7.5+1.1 pmoll h/mg protein and did not change significantly either after induction of anesthesia or after skin incision before heparin. A marked increase in plasma PLA2 activity was seen before CPB after administration of heparin, from 7.4+1.0 to 25.5±+3.5 pmol/ h/mg, P < 0.001. PLA2 activity remained elevated throughout the CPB period. Protamine, administered to neutralize the heparin, resulted in a marked decrease of PLA2 activity (to 13.8±2.1 pmollh/mg, P < 0.01 compared with values before protamine infusion), although PLA2 activity remained significantly higher than values before heparin administration. Neither heparin nor protamine affected enzyme activity when added to plasma in vitro (data not shown). Plasma heparin concentrations measured 5 min after the administration of heparin were 6.0, 6.7, and 7.6 U/ml in three patients. The heparin concentration was slightly higher (8.5 U/ml) in one patient in which it was measured 25 min after heparin administration and lower (3.4 and 3.1 U/ml) in two patients in which it was measured 5 min before protamine administration.
Plasma 6-keto-PGF,a and TXB2 concentration. No significant changes in plasma 6-keto-PGFi,a and TXB2 concentrations were observed after induction of anesthesia or after the initial surgical incision before heparin administration (Fig. 2) . Marked increases of plasma 6-keto-PGFi,, concentrations were measured after heparin administration (from 96±28 to 454±92 pg/ ml, P < 0.001), but heparin did not alter plasma TXB2. TXB2
concentrations increased significantly after initiation of CPB (from 124±20 to 197±36 pg/ml at 15 min on CPB, P < 0.05). levels were seen after heparin administration, while plasma TXB2 increased only after initiation of CPB (A). Protamine acutely reduced plasma levels of 6-keto-PGFI,1 but did not change TXB2 levels, thus the ratio of TXB2/6-keto-PGFI,a decreased after heparin and increased after protamine infusion (B). *P < 0.05, **P < 0.01, compared with controls, and #P < 0.05, compared with the values before protamine. n = 12 patients. Plasma 6-keto-PGF1,a (C) and TXB2 levels (D) plotted against PLA2 activity of plasma taken during CPB surgery. There was a close correlation between mean plasma 6-keto-PGFIat levels and PLA2 activity (C), whereas no correlation was found between PLA2 activity and TXB2 levels (D).
Protamine infusion acutely reduced plasma 6-keto-PGFi,a, from 370±100 to 200±47 pg/ml (Fig. 2 A, P < 0.001). Protamine did not change plasma TXB2 concentrations. Thus, the ratio of TXB2 to 6-keto-PGFia decreased after heparin from 2.22±0.64 to 0.49±0.21 and increased significantly after protamine infusion (to 1.85+0.57, Fig. 2 B, P < 0.05). Correlation of plasma PLA2 activity and plasma 6-keto-PGF,a and TXB2 levels during CPB surgery. To determine interrelationships between plasma PLA2 activity and plasma 6-ketoPGFia, mean 6-keto-PGFIa concentration at each operative period was plotted as a function of plasma PLA2 activity. As demonstrated in Fig. 2 C, there was a close correlation between plasma 6-keto-PGFia levels and PLA2 activity during surgery (y = 9.772x -63.34, r2 = 0.879). No correlation was found between plasma TXB2 levels and PLA2 activity (Fig. 2 D) . Effects of lower clinical doses of heparin on plasma PLA2 activity. PLA2 activity was measured in another group of patients who received a bolus of only 5,000 or 6,000 U of heparin. This dose of heparin had a significant effect on plasma PLA2 activity (12.3±1.1 pmollh/mg in post-heparin plasma vs 1.2+0.2 pmol/h/mg in pre-heparin plasma, P < 0.005, n = 3).
Thus, plasma PLA2 activity is increased in patients receiving amounts of heparin that are routinely used for therapy in the nonsurgical setting.
Characterization ofplasma PL42 activity. To further characterize post-heparin plasma PLA2 activity, samples were fractionated by Superose 12 gel filtration chromatography (Fig. 3) . Recovery of activity from the column was between 90 and 110%. Plasma PLA2 activity, measured using 2-[1-'4C]AA-GPE as substrate, both before and after heparin, migrated as a single peak of activity eluting in the same fraction as porcine pancreatic PLA2 with mobility characteristics corresponding to an approximate molecular mass of 14 kD. Greater peak and integrated activities were observed consistently in post-heparin plasma than in pre-heparin plasma.
There were additional features of the post-heparin plasma PLA2 which clearly distinguished it as group II PLA2. No increase in plasma PLA2 activity was measured during surgery a. (Fig. 4 A) . The identity of the post-heparin plasma PLA2 as a group I or II enzyme was further confirmed by its inhibition by pbromophenacyl bromide (BPB) and dithiothreitol (DTT). BPB inactivates group I and group II PLA2s by reacting specifically with 48His at the catalytic site (25) which is conserved among group I and group II forms (26) . BPB has no activity against cytosolic PLA2 (cPLA2) (22) . BPB inhibited plasma PLA2 activity by -80% (data not shown). DTT markedly inhibits human plasma PLA2 in a manner similar to its inhibition of group I and group II PLA2s (Fig. 4 B) . DTT has no effect on the large molecular mass cPLA2.
The calcium and pH dependencies of post-heparin PLA2 activities were also determined. The enzyme was Ca2' dependent, was maximally active at Ca2+ concentrations -50 1IM, and had a pH optimum of -8.5. Approximately one-half maximal activity was present at physiological pH of 7.4-7.5. These are properties typical for a group II PLA2 (data not shown).
We further characterized the PLA2 activity by heparin-5PW HPLC chromatography (Fig. 5) . On this column, group I is clearly distinguished from group LI PLA2 by elution at different NaCl concentrations. As shown in Fig. 5 , the elution pattem of plasma enzymatic activity is clearly that of group II.
The concentration dependency of inhibition with sodium deoxycholate is typical for group II PLA2 (Fig. 6 ) and is distinct from the pattem seen with group I or cPLA2. No PLC activity was identified since no radioactivity was found in the monoand diglyceride regions when PLA2 assay samples were separated by TLC.
Effects ofpatients' plasma on porcine PLA2 activity. When plasma (containing 25 Mug protein), taken at various times during surgery, was added to 50 ng of purified porcine pancreatic PLA2, there was no modulation of PLA2 activity regardless of when, during the course of the operation, the plasma was collected. In addition, actual and predicted activity of PLA2 was the same when plasma samples, collected before and after heparin administration, were mixed at various ratios. Thus, the patients' plasma did not contain any PLA2 activating or inhibiting factor detectable by this assay with pancreatic PLA2 even in the presence of heparin.
PLA2 activity in PMNs and release of PLA2 activity from PMNs into the medium by heparin. As demonstrated in Fig. 7 A, there was a dose-dependent increase in soluble PLA2 activity in PMNs when cells were treated with heparin. There was also a dose-dependent increase in PLA2 activity released into the medium when PMNs were incubated with heparin (Fig. 7 B) . In additional experiments (not shown) we found that PMNs isolated from patients on CPB receiving high dose heparin also 0-. Fraction Number Figure 5 . Heparin-5PW HPLC profile of post-heparin human plasma PLA2 activity. Plasma PLA2 was loaded onto a heparin affinity column. For comparison, rat platelet 100,000 g supematant was used as a standard for group II PLA2 and purified porcine pancreatic PLA2 diluted with buffer A (see Methods) containing 1 mg/ml bovine serum albumin as a group I standard. Each sample was applied to the same column under the same conditions. had higher levels of cellular PLA2 activity when compared with PMNs isolated before heparin therapy. PLA2 activity was not increased in the culture medium of human umbilical endothelial cells after exposure to heparin for periods up to 24 h (data not shown). Exposure of PMNs to protamine had no effect on cellular ( Fig. 8 A) or secreted (Fig. 8 B) PLA2 activity, but pretreatment with protamine completely prevented the increases in cellular and medium activities observed after heparin treatment. Gel filtration chromatography ofPMN soluble extracts and medium after heparin exposure. To partially characterize the heparin-induced PLA2 activation of PMNs, soluble cellular extracts and supernatants of intact PMNs exposed to heparin were fractionated by Superose 12 gel filtration chromatography. The glycerol. The mixture was vigorously vortexed for 15 s. Human postheparin plasma or PLA2 enzymes were then added and incubated at 37°C for 30 min. Released free fatty acid was extracted using Dole's extraction method as described in Methods. 100-kD cytosolic PLA2 was partially purified from bovine platelets with sequential uses of DEAESephacel, Butyl-Toyopearl, Sephacryl S-300, and DEAE-5PW HPLC as described previously (51) . In sodium deoxycholate-free assay, porcine pancreatic, rat platelet, bovine platelets, and human plasma PLA2 [38] ) than the PLA2 activf three experiments.
ity we have characterized (14 kD).
The increase of plasma PLA2 activity associated with heparin administration was highly correlated with concurrent ink of PLA2 activity in both soluble cellular fractions creases in plasma 6-keto-PGFi, levels during surgery. In pam migrated at the same position as the peak of activity tients with coronary disease, heparin increases the PGI2 concens seen in post-heparin plasma (Fig. 3) eo E PLA2 may be released from PMNs under other conditions. Plasma PLA2 activity is enhanced in experimental endotoxemia (43) . Patients with sepsis have elevated plasma 14-kD PLA2 activity (36) . Our experiments demonstrate no release of PLA2 activity from endothelial cells in response to heparin. It is possible, however, that a plasma factor, not present in these experiments in vitro, might potentiate the effect of heparin to release PLA2 from endothelial cells in vivo. Murakami et al. (44) have recently demonstrated that heparin addition after preexposure of cells to tumor necrosis factor for 6 h resulted in release of group H PLA2 from human umbilical vein endothelial cells. Platelets are another potential source of group II PLA2 (26) .
While our studies do not prove a direct cause and effect relationship between increases in plasma PLA2 activity and prostacyclin synthesis, the two are highly correlated, and we propose that the elevated plasma concentrations of group II PLA2 act directly on the endothelial cells to induce prostacyclin synthesis. When group II PLA2 is added to human umbilical vein endothelial cells there is a stimulation of prostacyclin release into the medium (44) .
Protamine sulfate administration to patients can result in severe pulmonary vasoconstriction (45) . Eicosanoids, in particular TXA2, have been implicated in this pathophysiological response to protamine (7-9, 11, 46-48) , and hemodynamic side effects of protamine have been prevented by pretreatment with a cyclooxygenase inhibitor (47) . In other studies, however, no significant changes were observed in eicosanoid levels after protamine administration (19, 49, 50) . In our study, protamine administration reverses heparin-enhanced plasma PLA2 activity and reduces plasma 6-keto-PGFIa levels. Protamine also prevented the release of PLA2 from PMNs. Because TXB2 did not change after protamine, the ratio of TXB2/6-keto-PGFIa, increased markedly. Thus, protamine-induced changes in the balance between the two prostanoids with opposing vasoactivities may account for some of the adverse effects of protamine.
In conclusion, we have demonstrated that plasma group II PLA2 activity is enhanced markedly during cardiac surgery and that this is due to heparin administration. This enhanced PLA2 activity in post-heparin plasma correlates highly with plasma concentrations of 6-keto-PGFia but not TXB2. Post-heparin PLA2 activity may derive in part from PMNs, but our data do not exclude other cells such as platelets and/or endothelial cells as potential sources for the plasma PLA2 activity. The anticoagulant, and possibly vasodilatory, effects of heparin might be due in part to enhanced plasma PLA2 activity with subsequent increases in plasma levels of PGI2. After protamine administration, plasma PLA2 activity and PGI2 concentrations are reduced. An increased ratio of TXB2/6-keto-PGFla may explain, at least in part, the pathophysiological consequences sometimes observed with protamine administration to patients.
